Jiangsu Hengrui Medicine
600276.SS
#459
Rank
S$59.43 B
Marketcap
$9.32
Share price
-0.54%
Change (1 day)
5.70%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): S$1.10 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are S$3.63 Billion. In 2023 the company made an earning of S$0.88 Billion, an increase over its 2022 earnings that were of S$0.79 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) S$1.10 B24.61%
2023 S$0.88 B11.4%
2022 S$0.79 B-13.65%
2021 S$0.92 B-34.21%
2020 S$1.40 B15.95%
2019 S$1.20 B33.03%
2018 S$0.90 B20.89%
2017 S$0.75 B23.89%
2016 S$0.60 B11.21%
2015 S$0.54 B39.5%
2014 S$0.39 B20.61%
2013 S$0.32 B11.46%
2012 S$0.29 B29.7%
2011 S$0.22 B31.16%
2010 S$0.17 B27.92%
2009 S$0.13 B5.8%
2008 S$0.12 B79.95%
2007 S$70.21 M32.89%
2006 S$52.83 M38.19%
2005 S$38.23 M21.56%
2004 S$31.45 M13.95%
2003 S$27.6 M38.06%
2002 S$19.99 M